PRCT

PROCEPT BioRobotics Corporation

Healthcare
Medical - Devices
$1.16B market cap

Forecast run · Sep 14, 2026Upside rank 547 of 3,136

Model Signal

ForecastQ Daily Probabilities

54.3%

41.2%

33.0%

Analyst Consensus

Recommendation2.50/5 Buy

Last price$20.38

Price target$22.13

Implied move+8.6%

Analysts16

ForecastQ Portfolios

PRCT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.